The Canadian Association of Pharmacy in Oncology Presents CAPhO - PDF document

The Canadian Association of Pharmacy in Oncology Presents CAPhO Oncology Fundamentals Day Saturday, October 1, 2016 www.capho.org #OFD16 www.acpho.org [Type here]

CAPhO Oncology Fundamentals Day Saturday, October 1, 2016 Accreditation CAPhO Oncology Fundamentals Day is accredited by the Canadian Council on Continuing Education in Pharmacy (CCCEP) for 6.67 continuing education credits (CEUs) . Participation on October 1 st is required to receive a letter of participation. CCCEP Number: 1152-2016-1830-C-P Program at a Glance Click on the session title or presenter name to go directly to the session description or presenter biography. Registrants of the event can download the presentation slides on the OFD website. Note: All times indicated are Eastern Daylight Times (EDT).The program below is subject to change. Time Session 09:30 – 09:40 Welcome Remarks 09:40 – 11:50 Fundamentals of Hematologic Cancer 09:40 – 10:20 Lymphoma - Kyla Marien, Tom Baker Cancer Clinic, Calgary, AB 10:25 – 11:05 Chronic Leukemias - Danica Wasney, CancerCare Manitoba, Winnipeg, MB 11:10 – 11:50 Multiple Myeloma - Tina Crosbie, The Ottawa Hospital, Ottawa, ON 11:50 – 12:30 Break 12:30 – 14:55 Fundamentals of Solid Tumours 12:30 – 13:15 Breast Cancer - Melanie Danilak, Alberta Health Services, Edmonton, AB 13:20 – 14:05 Colorectal Cancer - Tom McFarlane, University of Waterloo, Kitchener, ON 14:10 – 14:55 Lung Cancer - Jason Wentzell, The Ottawa Hospital, Ottawa, ON 14:55 – 15:20 Break 15:20 – 18:00 Chemotherapy Toxicity Management Chemotherapy Induced Nausea and Vomiting - Sally Waignein, BC Cancer 15:20 – 16:00 Agency, Vancouver, BC Other Gastro-Intestinal Toxicities - Glenn Myers, Horizon Health Network, 16:05 – 16:45 Moncton, NB Febrile Neutropenia - Tara Leslie, Tom Baker Cancer Centre/University of 16:50 – 17:20 Alberta, Calgary, AB 17:25 – 18:00 Skin, Nail and Hair Toxicities – Lynn Hartery , Eastern Health, St. John’s, NL 18:00 – 18:10 Closing Remarks Page | 2 #OFD16 www.capho.org

CAPhO Oncology Fundamentals Day Saturday, October 1, 2016 Session Descriptions and Presenter Biographies Fundamentals of Hematologic Cancers Lymphoma - Kyla Marien, Tom Baker Cancer Clinic, Calgary, AB Lymphomas are a heterogeneous group of over 40 different malignancies originating from T cells and B cells in the lymphatic system. Within this group of diseases there are similarities and differences within the pathophysiology, natural history, and prognosis. As treatment options differ dependent on the specific disease, the adverse effects patients experience can be diverse. Pharmacists are well positioned to assist in monitoring lymphoma patients for therapy toxicities and optimizing supportive care measures. Learning Objectives: 1. Appreciate the numerous types of lymphoma and gain understanding in the differences between Hodgkin and Non-Hodgkin, indolent and aggressive, and B- cell versus T-cell lymphoma; 2. Discuss the incidence, pathophysiology, typical presentation, and prognostic factors for lymphomas; 3. Describe some common treatment regimens, associated side effects, and monitoring parameters for common types of lymphoma; and 4. Explore the role of CD20 monoclonal antibodies in lymphoma and discuss the associated supportive care requirements. Download the presentation slides Kyla Marien graduated from University of Saskatchewan in 2003 and currently works for Alberta Health Services at the Tom Baker Cancer Centre as clinical hematology pharmacist. Over the past 13 years she has practiced in many diverse settings, including community, geriatrics, hospital outpatient, and oncology. Kyla truly believes each setting provided her with different skills and knowledge to allow her to practice today in oncology with an appreciati on for a patient’s experiences both in the center and in the community. Before joining the hematology clinical pharmacy team, Kyla developed her oncology clinical skills with the oral chemotherapy management clinic. Kyla is a proud CAPhO member. Page | 3 #OFD16 www.capho.org

CAPhO Oncology Fundamentals Day Saturday, October 1, 2016 Chronic Leukemias - Danica Wasney, CancerCare Manitoba, Winnipeg, MB Systemic therapy for both Chronic Lymphocytic Leukemia (CLL) and Chronic Myelogenous Leukemia (CML) has evolved significantly over the past 10-15 years. Systemic therapy for both CLL and CML is complex due to both the regimens used and the patient populations, as patients often present with comorbidities and multiple medications. Pharmacists are well equipped to optimize clinical outcomes for patients with CLL and CML through education, monitoring, symptom management, and medication management. For CLL, selection of systemic therapy is based on a variety of patient and disease factors, including staging, patient performance/functional status, and genetic markers. Systemic therapy regimens for CLL are complex, consisting of both oral and parenteral anticancer agents in addition to crucial supportive care agents. In addition, these regimens require careful attention with regards to drug interactions and medication adherence. Pharmacists can play a key role in optimizing care for patients with CLL. For CML, the introduction of targeted therapies has resulted in significant advances in patient survival and outcomes. Treatment selection is based on a variety of patient and disease factors, including CML phase, patient performance/functional status, and genetic markers. Since systemic therapies used to manage CML are usually orally administered on an outpatient basis, pharmacists are positioned to support patients with CML through management of drug interactions, symptom management, and medication adherence. Learning Objectives: After this presentation, participants should be able to: 1. Discuss the incidence, prevalence, pathophysiology, and staging for Chronic Lymphocytic Leukemia (CLL); 2. Discuss the incidence, prevalence, pathophysiology, and staging (phases) for Chronic Myelogenous Leukemia (CML); 3. Describe systemic treatment selection, monitoring parameters, and expected outcomes for patients with CLL and CML; and 4. Explain common supportive care issues for patients with CLL and CML. Download the presentation slides Danica Wasney is a Clinical Pharmacist for the Provincial Oncology Drug Program at CancerCare Manitoba. In this role, she participates in the provincial oncology drug review process including the management of the provincial oncology drug formulary. She is a member of the Expert Review Committee for the pan-Canadian Oncology Drug Review (pCODR) at the Canadian Agency for Drugs and Technologies in Health (CADTH). Danica has clinical experience in breast, colorectal, thoracic and gynecologic cancers, neuro-oncology, and hematologic malignancies. Page | 4 #OFD16 www.capho.org

CAPhO Oncology Fundamentals Day Saturday, October 1, 2016 Danica graduated from the Faculty of Pharmacy at University of Manitoba and completed an Accredited Hospital Pharmacy Residency at The Ottawa Hospital. She is a Board Certified Oncology Pharmacist, a member of the CAPhO Research Committee, and a past member of the CAPhO Education Committee. Page | 5 #OFD16 www.capho.org

CAPhO Oncology Fundamentals Day Saturday, October 1, 2016 Multiple Myeloma - Tina Crosbie, The Ottawa Hospital, Ottawa, ON Multiple Myeloma is the second most common blood cancer. Every day, seven Canadians are diagnosed with myeloma; most commonly people are in their early 60’s at diagnosis. Myeloma can affect other parts of a person’s body including the kidneys and bones. Knowing what a patient can expect when diagnosed with myeloma can help the pharmacist be a valued resource when providing care to that patient. 2016 has seen a wealth of treatment options for patients with multiple myeloma. The pharmacist is in a great position to explain the treatment chosen to manage the disease and answer questions so the patient can benefit from their therapy. Learning Objectives: 1. Define myeloma and how frequently it occurs in Canada; 2. Discuss how a patient may appear when ready to start myeloma therapy; 3. Identify key patient needs and how the pharmacist can assist their patient with myeloma; and 4. Review what treatment combinations are available for patients with newly diagnosed and for patients with relapsed myeloma. Download the presentation slides Tina Crosbie holds a Bachelor of Science in Pharmacy from Memorial University of Newfoundland and completed her hospital pharmacy residency at The Ottawa Hospital. She has over 20 years experience in hospital and retail pharmacy practice in Newfoundland and Ontario. For the last 17 years Tina has been part of the hematology team at The Ottawa Hospital. Currently, she is the clinical pharmacist for the ambulatory hematology chem unit. Here she oversees patients with lymphoma, multiple myeloma and chronic lymphocytic leukemia who are receiving care on an outpatient basis. Tina has written educational materials and has given presentations on numerous topics in hematology. She also enjoys being a peer reviewer for the Canadian Council on Continuing Education in Pharmacy (CCCEP), and is a proud member of CAPhO. Page | 6 #OFD16 www.capho.org